Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04321070 · ClinicalTrials.gov registry record · Phase 1
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 550
- Enrollment target
NCT04321070: Completed Phase 1 study, sponsored by Sun Pharmaceutical Industries.
NCT04321070 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 550 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (817% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04321070, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 550 participants
- Enrollment target
Study Summary
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
Primary Outcome
Demonstration of Bioequivalence in percent change in inflammatory and non-inflammatory lesion counts
Interventions
- DRUG Placebos
- DRUG Clindamycin Phosphate
- DRUG Clindamycin Phosphate RLD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2020-03-06 |
| Phase | Phase 1 |
What the finished NCT04321070 record still lists
NCT04321070 is an interventional study that assigns participants to a tested intervention. The registered 550 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (817% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebos is the first listed.
NCT04321070 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04321070 about?
NCT04321070 is a clinical study titled "Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris". Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
What is the current status of trial NCT04321070?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 550 participants. The study started on 2019-09-09. Estimated completion is 2020-03-06.
What interventions are being tested in trial NCT04321070?
The interventions under investigation include: Placebos (DRUG), Clindamycin Phosphate (DRUG), Clindamycin Phosphate RLD (DRUG).
Who is sponsoring clinical trial NCT04321070?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04321070's enrollment target sits among peer trials
550 35th of 2000 higher than 1,966 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI